Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03523520 · ClinicalTrials.gov registry record · Phase 4
Methylnaltrexone vs Naloxegol in the Treatment of Opioid-Induced Constipation
A Phase 4 study, sponsored by University of Missouri-Columbia.
- Completed
- Registry status
- Phase 4
- Development phase
- 15
- Enrollment target
NCT03523520 is a Phase 4 study that has completed, run by University of Missouri-Columbia. The registered enrollment target is 15 participants.
The verdict
NCT03523520, a Phase 4 study, has completed, sponsored by University of Missouri-Columbia.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 15 participants
- Enrollment target
Study Summary
The purpose of this study is to compare the efficacy of subcutaneous versus oral mu-opioid receptor antagonist therapy in opioid induced constipation that is refractory to other bowel regimens.
Interventions
- DRUG Methylnaltrexone Bromide 150 mg Oral Tablet
- DRUG Methylnaltrexone Bromide 12 MG/0.6 ML Subcutaneous Solution [RELISTOR]_#1
- DRUG Naloxegol 25 MG Oral Tablet
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2020-12-23 |
| Est. Completion | 2023-03-31 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03523520
The ClinicalTrials.gov registry entry for NCT03523520 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Missouri-Columbia, which has 291 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Methylnaltrexone Bromide 150 mg Oral Tablet is the first listed.
NCT03523520 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03523520 about?
NCT03523520 is a clinical study titled "Methylnaltrexone vs Naloxegol in the Treatment of Opioid-Induced Constipation". The purpose of this study is to compare the efficacy of subcutaneous versus oral mu-opioid receptor antagonist therapy in opioid induced constipation that is refractory to other bowel regimens.
What is the current status of trial NCT03523520?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 15 participants. The study started on 2020-12-23. Estimated completion is 2023-03-31.
What interventions are being tested in trial NCT03523520?
The interventions under investigation include: Methylnaltrexone Bromide 150 mg Oral Tablet (DRUG), Methylnaltrexone Bromide 12 MG/0.6 ML Subcutaneous Solution [RELISTOR]_#1 (DRUG), Naloxegol 25 MG Oral Tablet (DRUG).
Who is sponsoring clinical trial NCT03523520?
This trial is sponsored by University of Missouri-Columbia, which has 291 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.